Presentation and outcomes of patients with clinically T1-2, N0 parotid mucoepidermoid carcinoma: The roles of elective neck dissection and adjuvant radiotherapy

Zaid Al-Qurayshi MBChB, MPH1 | Christopher Blake Sullivan MD2 | Derek B. Allison MD3 | Marisa R. Buchakjian MD, PhD1

Abstract
Objectives: Examine the role of elective neck dissection (END) and adjuvant radiotherapy (RT) in early-stage clinically N0 parotid mucoepidermoid carcinoma (MEC).

Methods: The study is a retrospective analysis of the National Cancer Database, 2004–2016. The study population included adult patients with MEC who underwent parotidectomy.

Results: A total of 1233 patients were included. Histopathology demonstrated well, moderately, and poorly differentiated MEC 47.12%, 39.98%, and 12.90% of the time, respectively. END was performed in 78.67% of patients, resulting in nodal upstaging in 4.43% and identification of extracapsular extension (ECE) in 0.72%. RT was utilized in 67.33% of patients with advanced pathological features. Neither END nor RT improved overall survival separately (p < 0.05) or combined (adjusted HR: 1.19, 95%CI: 0.52, 2.70, p = 0.68).

Conclusion: This study provides an epidemiological perspective regarding patients with clinically T1-2, N0 MEC. There was no observed survival advantage with END and RT.

Keywords: epidemiology, facial nerve, mucoepidermoid carcinoma, neck dissection, parotidectomy, radiotherapy, survival

1 | INTRODUCTION

Mucoepidermoid carcinoma (MEC) is the most common malignant neoplasm of major and minor salivary glands and occurs most often in the parotid gland.1 Although MEC comprises less than 1% of all malignancies, it accounts for almost 30% of malignant salivary gland neoplasms.2,3 The incidence of MEC is highest in women between the third and fifth decade of life.3,4

MEC tumors are composed of mucin-secreting, intermediate, and epidermoid cells.1,5 MEC may show variably cystic and solid growth patterns and frequently contains a tumor-associated lymphoid proliferations...

Zaid Al-Qurayshi and Christopher Blake Sullivan contributed equally to this study.
| Study population, \( N = 1,233 \) (%) | Grade (%) | Grade (%) | Grade (%) | Grade (%) | p-value |
|-------------------------------------|-----------|-----------|-----------|-----------|---------|
| \( \text{Well differentiated, } n = 581 \) | \( \text{Moderately differentiated, } n = 493 \) | \( \text{Poorly differentiated, } n = 159 \) | |
| Age (year) | | | | | |
| <65 | 845 (68.53) | 417 (71.77) | 360 (73.02) | 68 (42.77) | <0.001 |
| ≥65 | 388 (31.47) | 164 (28.23) | 133 (26.98) | 91 (57.23) | |
| Sex | | | | | |
| Male | 479 (38.85) | 209 (35.97) | 177 (35.9) | 93 (58.49) | <0.001 |
| Female | 754 (61.15) | 372 (64.03) | 316 (64.1) | 66 (41.51) | |
| Charlson/Deyo score | | | | | |
| 0 | 992 (80.45) | 461 (79.35) | 405 (82.15) | 126 (79.25) | 0.48 |
| 1 | 183 (14.84) | 88 (15.15) | 67 (13.59) | (12.03–24.44) | |
| ≥2 | 58 (4.7) | 32 (5.51) | 21 (4.26) | (01.03–07.19) | |
| Laterality | | | | | |
| Right parotid gland | 626 (50.77) | 288 (49.57) | 258 (52.33) | 80 (50.31) | 0.66 |
| Left parotid gland | 607 (49.23) | 293 (50.43) | 235 (47.67) | 79 (49.69) | |
| Surgery | | | | | |
| Superficial parotidectomy | 717 (58.15) | 348 (59.9) | 298 (60.45) | 71 (44.65) | 0.001 |
| Total parotidectomy | 516 (41.85) | 233 (40.1) | 195 (39.55) | 88 (55.35) | |
| Facial nerve | | | | | |
| Preserved | 921 (74.7) | 439 (75.56) | 383 (77.69) | 99 (62.26) | <0.001 |
| Sacrificed | 312 (25.3) | 142 (24.44) | 110 (22.31) | 60 (37.74) | |
| Elective neck dissection | | | | | |
| Not performed | 263 (21.33) | 124 (21.34) | 108 (21.91) | 31 (19.5) | 0.81 |
| Performed | 970 (78.67) | 457 (78.66) | 385 (78.09) | 128 (80.5) | |
| Pathological T | | | | | |
| 1 | 784 (63.58) | 406 (69.88) | 330 (66.94) | 48 (30.19) | <0.001 |
| 2 | 354 (28.71) | 154 (26.51) | 121 (24.54) | 79 (49.69) | |
| 3 | 68 (5.52) | (01.85–04.85) | (04.48–09.04) | (06.71–18.59) | |
| 4a | 27 (2.19) | (00.11–01.50) | (00.98–03.70) | (00.86–07.81) | |
| Outcome of elective neck dissection | | | | | |
| Pathological N0 | 920 (94.85) | 448 (98.03) | 363 (94.29) | 109 (85.16) | <0.001 |
| Pathological N+ without ECE | (03.23–05.93) | (00.76–03.42) | (03.20–07.91) | (06.71–18.59) | |
| Pathological N+ with ECE | (00.29–01.48) | (00.01–01.21) | (00.06–01.86) | (00.86–07.81) | |
| Surgical margins | | | | | |
| Negative | 998 (80.94) | 499 (85.89) | 389 (78.9) | 110 (69.18) | <0.001 |
| Positive | 235 (19.06) | 82 (14.11) | 104 (21.1) | 49 (30.82) | |
| Lymphovascular invasion | | | | | |
| Not present | 745 (96.63) | (97.67–99.83) | (94.90–98.86) | 77 (83.7) | <0.001 |
| Present | 26 (3.37) | (00.17–02.33) | (01.14–05.10) | 15 (16.3) | |
| T3-4a, LVI, N+, ECE, and/or positive surgical margins | | | | | |
| Not present | 905 (73.40) | 479 (82.44) | 350 (70.99) | 76 (47.80) | <0.001 |
| Present | 328 (26.60) | 102 (17.56) | 143 (29.01) | 83 (52.20) | |
around the invading edges. There are several well-characterized histologic variants, including oncocytic, clear cell, sclerosing, solid, Warthin-like, and others. Despite this morphologic diversity, most MECs harbor a MAML2 gene fusions, which is specific to MEC and often helpful diagnostically.

There is no universally accepted grading system, and as a result, multiple grading systems exist. However, most grading systems are three-tiered, with most tumors stratified from low, intermediate, or high grade based on the presence of various histopathologic features, including growth pattern (cystic versus solid, well-circumscribed versus infiltrative), mitotic activity, necrosis, perineural invasion, lymphovascular invasion, and nuclear pleomorphism, among others. Lower grade tumors are often more cystic and well-circumscribed, while higher grade tumors tend to be more solid and infiltrative with the aggressive aforementioned features.

The 5-year overall survival (OS) of MEC is 70.2%. Factors associated with poor survival include older age, increasing comorbidities, histologic grade, advanced stage tumors, and positive surgical margins. Surgical excision is the primary treatment modality for MEC. However, the role of an elective neck dissection (END) in early-stage tumors with clinically negative necks, including no lymphadenopathy on physical examination or diagnostic imaging, is variable given the lack of randomized clinical trials and treatment guidelines. END is routinely performed in patients with locoregional cervical nodal metastasis or high-grade lesions. Additionally, the role of adjuvant radiotherapy (RT) and/or chemotherapy for MEC is not completely understood and tends to be physician- or institution-dependent, with chemotherapy being used in the palliative setting for advanced or recurrent disease. The objective of the current study is to examine the epidemiological characteristics and treatment

| TABLE 1 (Continued) | Study population, N = 1,233 (%) | Grade (%) | Adjuvant radiotherapy |
|----------------------|-------------------------------|-----------|----------------------|
|                      | Well differentiated, n = 581  |           | Not performed        |
|                      |                               |           | 793 (64.31)          |
|                      |                               |           | 452 (77.8)           |
|                      |                               |           | 308 (62.47)          |
|                      |                               |           | 33 (20.75)           |
|                      | Moderately differentiated, n = 493 |           | Performed           |
|                      |                               |           | 440 (35.69)          |
|                      |                               |           | 129 (22.2)           |
|                      |                               |           | 185 (37.53)          |
|                      | Poorly differentiated, n = 159|           |                      |
|                      |                               |           | 126 (79.25)          |

Abbreviations: ECE, extracapsular extension; LVI, lymphovascular invasion.

aPercentage values add-up vertically and may not add up to 100% due to rounding.

bChi-square test.

This range represents 95% confidence interval. Data-using-agreement prohibits reporting exact number of subjects for variables with less than 10 subjects with the event so it was substituted with 95% confidence interval to convey an estimate.

dLymphovascular invasion variable is missing for 462 subjected because it is only available for the years 2010–2016.

FIGURE 1 Probability of advanced pathological features in patients with clinically T1-2, N0 parotid mucoepidermoid carcinoma who underwent surgical resection [Color figure can be viewed at wileyonlinelibrary.com]
patterns among patients with clinically T1-2, N0 MEC of the parotid gland.

2 | MATERIALS AND METHOD

This study is a retrospective cohort analysis utilizing the National Cancer Database (NCDB) from 2004 to 2016. The NCDB is a joint program between the American College of Surgeons (ACS) and the American Cancer Society that contains data collected from facilities accredited by the Commission on Cancer. The NCDB, established in 1989, is a nationwide, facility-based, comprehensive clinical surveillance resource with an oncology data set that currently captures 70% of all newly diagnosed malignancies in the United States annually. The NCDB is de-identified data that does not meet the criteria of human subject research and does not meet the criteria of review by the University of Iowa Institutional Review Board. The ACS and Commission on Cancer (CoC) have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

The objective of the study is to describe the presentation and management of patients with T1-2, N0 parotid MEC with a focus on the practice patterns of elective neck dissection and adjuvant radiotherapy, as well as their impact on OS.

The study population included adult patients (age ≥18 years) who were diagnosed with clinically T1-2, N0 parotid MEC. MEC was identified based on the International Classification of Diseases for Oncology third edition (ICD-O-3: 8430). The study population was classified based on grade of tumor differentiation and based on the absence or presence of one or more advanced pathological features, including poorly differentiated tumor, pathological T3-4a, positive lymph node(s), positive surgical margins, lymphovascular invasion (LVI), and extracapsular

![Figure 2](wileyonlinelibrary.com)
**TABLE 2  Multivariate analysis of factors associated with likelihood of identifying positive lymph node(s) on neck dissection of patients with clinically T1-2, N0 mucoepidermoid carcinoma**

| % positive LN(s) on pathology | OR* | 95%CI         | p-value |
|------------------------------|-----|--------------|---------|
| Grade                        |     |              |         |
| Well differentiated           | 1.97| Reference    |         |
| Moderately differentiated     | 5.71| 3.84, 12.01  | 0.021   |
| Poorly differentiated         | 14.84| 1.40, 18.48 | 0.014   |
| Pathological T                |     |              |         |
| 1–2                          | 3.92| Reference    |         |
| 3–4                          | 19.23| 3.05, 7.99  | 0.023   |
| Surgical margins             |     |              |         |
| Negative                     | 3.77| Reference    |         |
| Positive                     | 11.43| 2.63, 6.12  | 0.025   |
| Lymphovascular invasion      |     |              |         |
| Not present                  | 3.62| Reference    |         |
| Present                      | 22.73| 4.53, 15.05 | 0.014   |

Abbreviations: CI, confidence interval; ECE, extracapsular extension; LN, lymph node; OR, odds ratio.

*Multivariate logistic regression model included all the variables listed in the table except lymphovascular invasion as it was analyzed in a separate model that also included the other variables because lymphovascular invasion was only available for years 2010–2016.

**FIGURE 3  Prevalence of adjuvant radiotherapy utilization in relation to the study period and the presence of advanced pathological features (poorly differentiated, T3-4a, lymphovascular invasion, extracapsular extension, positive surgical margins) in patients with clinically T1-2, N0 parotid mucoepidermoid carcinoma who underwent surgical resection** [Color figure can be viewed at wileyonlinelibrary.com]
extension (ECE). It should be noted that LVI was available only for the years 2010–2016. The data were checked for completeness of other study parameters and patients with missing values were excluded.

Independent variables of interest included the following: age, sex, Charlson/Deyo score as reported in the NCDB, laterality, type of parotidectomy (superficial vs. total), and whether the facial nerve was preserved or sacrificed.

Chi-square was used to assess for the association of each independent factor with tumor grade, probability of undergoing elective neck dissection, and probability of utilizing adjuvant radiotherapy. Variables that demonstrated significant association were included in the multivariate logistic regression models that were used to calculate odds ratio (OR) and 95% confidence interval (95%CI). Log-rank test was performed to assess the association of each independent variable with OS. Variables that demonstrated significant association were included in the multivariate Cox hazard ratio (HR) models. Cox hazard ratio was also used to examine and control for time-interaction terms of each independent factor. Significant level was set as ($\alpha = 0.05$). All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC).

### 3 | RESULTS

A total of 1233 patients were included. Characteristics of the study population are listed in Table 1. The mean age of patients at the time of diagnosis was $55.80 \pm 15.90$ years, 61.15% were female, and 80.45% had a Charlson/Deyo score of 0. Median follow-up time was 57.69 months (interquartile range: 35.71–91.30 months).

The majority of patients underwent a superficial parotidectomy (58.15%), elective neck dissection (78.67%), and the preservation of the facial nerve (74.70%). Facial nerve sacrifice was significantly higher in patients who underwent total parotidectomy compared to superficial parotidectomy (30.81% vs. 21.34%, $p < 0.001$). It is worth noting that the NCBD does not specify if the sacrifice of the

| TABLE 3 | Multivariate analysis of factors associated with likelihood of utilizing adjuvant radiotherapy in patients with clinically T1-2, N0 mucoepidermoid carcinoma who underwent surgical resection |
| --- | --- | --- | --- | --- |
| % adjuvant radiotherapy | OR\textsuperscript{a} | 95%CI | $p$-value |
| Surgery | | | | |
| Superficial parotidectomy | 31.66 | | Reference |
| Total parotidectomy | 41.28 | 1.03 | 0.72, 1.46 | 0.89 |
| Grade | | | | |
| Well differentiated | 22.20 | | Reference |
| Moderately differentiated | 37.53 | 1.94 | 1.35, 2.79 | <0.001 |
| Poorly differentiated | 79.25 | 12.16 | 6.69, 22.12 | <0.001 |
| Pathological T | | | | |
| 1–2 | 32.78 | | Reference |
| 3–4 | 70.53 | 2.45 | 1.29, 4.68 | 0.006 |
| Elective neck dissection outcomes | | | | |
| Elective neck dissection not performed | 34.22 | 0.67 | 0.43, 1.03 | 0.07 |
| Pathological N0 | 33.80 | | Reference |
| Pathological N+ without ECE | 76.74 | 4.94 | 1.54, 15.81 | 0.007 |
| Pathological N+ with ECE | 85.71 | 0.24 | 0.01, 11.57 | 0.47 |
| Surgical margins | | | | |
| Negative | 28.56 | | Reference |
| Positive | 65.96 | 3.68 | 2.42, 5.59 | <0.001 |
| Lymphovascular invasion | | | | |
| Not present | 33.02 | | Reference |
| Present | 69.23 | 1.44 | 0.52, 4.02 | 0.48 |

Abbreviations: CI, confidence interval; ECE, extracapsular extension; OR, odds ratio.

\textsuperscript{a}Multivariate logistic regression model included all the variables listed in the table except lymphovascular invasion as it was analyzed in a separate model that also included the other variables because lymphovascular invasion was only available for year 2010–2016.
| Group                                         | Factor                                                                 | % 5-year overall survival | HR*          | 95%CI          | p-value |
|-----------------------------------------------|------------------------------------------------------------------------|---------------------------|--------------|----------------|---------|
| No advanced pathological features             | Age (year)                                                            |                           |              |                |         |
|                                               | <65                                                                    | 97.53                     | Reference    |                |         |
|                                               | ≥65                                                                    | 86.15                     | 4.58         | 2.77, 7.59     | <0.001  |
|                                               | Sex                                                                    |                           |              |                |         |
|                                               | Male                                                                   | 90.79                     | 2.22         | 1.36, 3.60     | 0.001   |
|                                               | Female                                                                 | 95.99                     | Reference    |                |         |
|                                               | Charlson/Deyo score                                                    |                           |              |                |         |
|                                               | 0                                                                      | 94.39                     | Reference    |                |         |
|                                               | 1                                                                      | 92.00                     | 1.33         | 0.75, 2.33     | 0.33    |
|                                               | ≥2                                                                     | 90.81                     | 1.46         | 0.45, 4.75     | 0.53    |
|                                               | Surgery                                                                |                           |              |                |         |
|                                               | Superficial parotidectomy                                              | 96.02                     | Reference    |                |         |
|                                               | Total parotidectomy                                                    | 90.88                     | 4.06         | 1.61, 10.26    | 0.003   |
|                                               | Facial nerve                                                           |                           |              |                |         |
|                                               | Preserved                                                              | 94.82                     | Reference    |                |         |
|                                               | Sacrificed                                                             | 91.90                     | 1.56         | 0.92, 2.65     | 0.10    |
|                                               | Elective neck dissection/adjuvant radiotherapy performed               |                           |              |                |         |
|                                               | No/no                                                                  | 95.61                     | 1.54         | 0.60, 3.90     | 0.37    |
|                                               | Yes/no                                                                 | 93.85                     | 1.46         | 0.69, 3.12     | 0.32    |
|                                               | No/yes                                                                 | 89.35                     | 2.42         | 0.78, 7.47     | 0.13    |
|                                               | Yes/yes                                                                | 97.38                     | Reference    |                |         |
| One or more advanced pathological features    | Age (year)                                                            |                           |              |                |         |
| (poorly differentiated, T3-4A, positive      | <65                                                                    | 93.09                     | Reference    |                |         |
| lymph node(s), positive surgical margins,     | ≥65                                                                    | 65.12                     | 6.13         | 3.59, 10.45    | <0.001  |
| lymphovascular invasion, extracapsular       | Sex                                                                    |                           |              |                |         |
| extension)                                    | Male                                                                   | 76.78                     | 1.24         | 0.78, 1.96     | 0.37    |
|                                               | Female                                                                 | 86.60                     | Reference    |                |         |
|                                               | Charlson/Deyo score                                                    |                           |              |                |         |
|                                               | 0                                                                      | 85.66                     | Reference    |                |         |
|                                               | 1                                                                      | 67.58                     | 1.47         | 0.86, 2.50     | 0.16    |
|                                               | ≥2                                                                     | 77.00                     | 2.96         | 1.24, 7.08     | 0.014   |
|                                               | Surgery                                                                |                           |              |                |         |
|                                               | Superficial parotidectomy                                              | 85.90                     | Reference    |                |         |
|                                               | Total parotidectomy                                                    | 79.57                     | 2.26         | 1.07, 4.78     | 0.034   |
|                                               | Facial nerve                                                           |                           |              |                |         |
|                                               | Preserved                                                              | 85.75                     | Reference    |                |         |
|                                               | Sacrificed                                                             | 79.88                     | 1.20         | 0.75, 1.93     | 0.44    |
|                                               | Elective neck dissection/adjuvant radiotherapy performed               |                           |              |                |         |
|                                               | No/no                                                                  | 87.50                     | 1.19         | 0.52, 2.70     | 0.68    |
|                                               | Yes/no                                                                 | 81.32                     | 1.41         | 0.82, 2.43     | 0.21    |
|                                               | No/yes                                                                 | 80.97                     | 0.93         | 0.48, 1.77     | 0.82    |
|                                               | Yes/yes                                                                | 86.00                     | Reference    |                |         |

Abbreviations: CI, confidence interval; HR, hazard ratio.

*Multivariate Cox hazard ratio model includes all the variables in the table.
facial nerve involved the main trunk or a branch of the facial nerve. The prevalence of well, moderately, and poorly differentiated MEC was 47.12%, 39.98%, and 12.90%, respectively. Surgical margins were negative in 80.94% of patients, and lymphovascular invasion was absent in 96.63% of patients. T classification was upstaged in 11.52% of the patients (Figure 1).

Among patients who underwent elective neck dissection, 94.9% of patients were pathologically N0. The performance of elective neck dissection tended to decrease over the study period (p = 0.013) (Figure 2). Elective neck dissection was not associated in the univariate analysis with any of the demographic or clinical factors so multivariate logistic regression for the probability of performing elective neck dissection was not performed. In patients who underwent neck dissection, the odds of identifying positive lymph node(s) was significantly associated in the multivariate model with poorly/moderately differentiated tumor, pathological T3-4, positive surgical margins, and presence of lymphovascular invasion (Table 2).

RT was performed in 35.7% of patients. RT annual utilization in relation to MEC pathological features are demonstrated in Figure 3. There was no significant trend in utilization throughout the study period. Patient factors that were associated with higher likelihood of RT utilization included poorly differentiated tumors (OR 12.16, 95%CI 6.69–22.12; p < 0.001), pathological T3 or T4 tumors (OR 2.45, 95%CI 1.29–4.68; p = 0.006), and positive surgical margins (OR 3.68, 95%CI 2.42–5.59; p < 0.001) (Table 3).

Among patients with no adverse pathological features, age 65 years and older (adjusted HR 4.58, 95%CI 2.77–7.59; p < 0.001), male sex (adjusted HR 2.22, 95%CI

![Figure 4](https://wileyonlinelibrary.com/)
Future

In a systematic review of 2202 patients, these tumors are relatively rare with con-

Similarly, Lau et al. assessed the risk of occult nodal metastasis among patients with and without adverse pathological features, age 65 years and older (adjusted HR 6.13, 95%CI 3.59–10.45; p < 0.001), Charlson/Deyo score ≥2 (adjusted HR 2.96, 95%CI 1.24–7.08; p = 0.014), and total parotidectomy (adjusted HR 2.26, 95%CI 1.07–4.78; p = 0.34) were associated with worse OS. Comparing the two groups, OS was worse among patients with one or more advanced pathological feature (Figure 4). In analyzing the addition of an elective neck dissection, adjuvant radiotherapy, or both in combination, there was no effect observed on OS.

4 | DISCUSSION

MEC comprises 30% of all major salivary gland tumors, but the incidence of MEC of the parotid gland is only 2.3 per 1000000. These tumors are relatively rare with consid-

Clinical staging relies on physical examination and preoperative imaging, including computed tomography and in some instances magnetic resonance imaging. Disparities exist between clinical and pathological staging for salivary gland MEC. Similar to other head and neck cancers, the discrepancy may be due to clinical staging failure or, perhaps, tumor progression prior to surgery. The current study provides useful information about pathological upstaging for T1-2, N0 MEC of the parotid gland. Importantly, we found that OS was not improved with END and/or RT.

The type of parotidectomy for early salivary gland cancers, either extracapsular or partial with or without facial nerve dissection, is a topic of debate. Some advocates for a partial parotidectomy when the tumor is cancerous due to the risk of indistinct or infiltrative margins. However, a retrospective series of 30 patients who had a preoperative diagnosis of a benign parotid gland tumor, but were found to have a malignancy on histopathology after an extracapsular dissection, did not have adverse outcomes on survival. The aforementioned study was a small case series, and the study may not be adequately powered to fully address this question. In a study by Mantzopoulos et al. that included nine patients with primary low-grade parotid malignant neoplasms who underwent extracapsular dissection, they demonstrated 5-year disease-specific survival of 100%. In a systematic review of 2202 patients by Guntinas-Lichius et al., they identified intraparotid metastasis as a negative prognostic factor for primary parotid gland cancer. There is still a controversy regarding extent of parotidectomy (total vs. superficial) for tumors confined to the superficial lobe with superficial intraparotid lymph node metastasis and cervical metastasis without deep lobe intraparotid metastasis. Future studies are warranted to better delineate the role of intraparotid lymph node metastasis.

A parotidectomy, whether partial or total, is standard of care for MEC, but management of the neck is physi-

The type of parotidectomy for early salivary gland cancers, either extracapsular or partial with or without facial nerve dissection, is a topic of debate. Some advocates for a partial parotidectomy when the tumor is cancerous due to the risk of indistinct or infiltrative margins. However, a retrospective series of 30 patients who had a preoperative diagnosis of a benign parotid gland tumor, but were found to have a malignancy on histopathology after an extracapsular dissection, did not have adverse outcomes on survival. The aforementioned study was a small case series, and the study may not be adequately powered to fully address this question. In a study by Mantzopoulos et al. that included nine patients with primary low-grade parotid malignant neoplasms who underwent extracapsular dissection, they demonstrated 5-year disease-specific survival of 100%. In a systematic review of 2202 patients by Guntinas-Lichius et al., they identified intraparotid metastasis as a negative prognostic factor for primary parotid gland cancer. There is still a controversy regarding extent of parotidectomy (total vs. superficial) for tumors confined to the superficial lobe with superficial intraparotid lymph node metastasis and cervical metastasis without deep lobe intraparotid metastasis. Future studies are warranted to better delineate the role of intraparotid lymph node metastasis.

A parotidectomy, whether partial or total, is standard of care for MEC, but management of the neck is physi-

The type of parotidectomy for early salivary gland cancers, either extracapsular or partial with or without facial nerve dissection, is a topic of debate. Some advocates for a partial parotidectomy when the tumor is cancerous due to the risk of indistinct or infiltrative margins. However, a retrospective series of 30 patients who had a preoperative diagnosis of a benign parotid gland tumor, but were found to have a malignancy on histopathology after an extracapsular dissection, did not have adverse outcomes on survival. The aforementioned study was a small case series, and the study may not be adequately powered to fully address this question. In a study by Mantzopoulos et al. that included nine patients with primary low-grade parotid malignant neoplasms who underwent extracapsular dissection, they demonstrated 5-year disease-specific survival of 100%. In a systematic review of 2202 patients by Guntinas-Lichius et al., they identified intraparotid metastasis as a negative prognostic factor for primary parotid gland cancer. There is still a controversy regarding extent of parotidectomy (total vs. superficial) for tumors confined to the superficial lobe with superficial intraparotid lymph node metastasis and cervical metastasis without deep lobe intraparotid metastasis. Future studies are warranted to better delineate the role of intraparotid lymph node metastasis.

A parotidectomy, whether partial or total, is standard of care for MEC, but management of the neck is physi-
Treatment patterns are often based on the National Comprehensive Cancer Network's salivary gland cancer guidelines. For early T classification (T1, T2) salivary gland cancers, consideration of RT is warranted with tumor spillage, perineural invasion, or intermediate or high-grade tumors. Given the lack of consensus for histologic grading of salivary gland MEC, there is potential for interobserver variability in RT treatment recommendations. In the present study, patients with tumors that were pathologically upstaged or had positive surgical margins were more likely to undergo RT. However, RT was not associated with improved OS. The role of RT in MEC of the parotid gland is not clearly defined and remains a controversial topic. In an analysis of 47 patients with early stage MEC of the salivary glands and a known favorable genetic mutation, Okumura et al. reported a 60 month median survival rate of 100% after surgical resection without RT. While OS benefit was not seen with RT, caution must be employed. Direct comparison of surgery alone versus surgery with RT has the potential of selection bias as the patients who underwent RT are more likely to have advanced disease. Additionally, the NCDB does not code for disease-specific survival. Future prospective clinical trials are warranted to validate the present findings.

The role of facial nerve function is a key consideration for any patient undergoing a parotidectomy. Preoperative facial nerve dysfunction is believed to be the result of direct tumor invasion, perineural invasion, or interruption of the blood supply to the nerve. Weakness of the nerve preoperatively is a known predictor of facial nerve sacrifice during parotidectomy. Proper oncologic management should not be prevented by preserving the facial nerve. Facial nerve paralysis is most common with undifferentiated carcinoma (24%) compared to MEC (9%). We found that 75% of patients with early stage MEC were able to have their facial nerve preserved. It is worth noting that the NCBD does not specify if the sacrifice of the facial nerve involved the main trunk or a branch of the facial nerve. A study of 75 patients with parotid malignancy found that they were able to spare the nerve in 60% of patients. Facial nerve sacrifice was not associated with worse OS in patients with no adverse features or in patients with adverse features. The decision to sacrifice the nerve has significant functional and cosmetic consequences, and this data provides physicians with relevant information to help counsel patients preoperatively about the potential for facial nerve preservation.

There are inherent and multiple limitations to the present study. Causality cannot be established as this is a retrospective cohort study. There is a lack of information regarding preoperative imaging studies and operative details. The database does not have information regarding the decision-making process and reasons behind choosing certain management. Furthermore, a lack of centralized pathologic review and reassessment of adverse pathologic features may result in some inconsistent results; however, data from such a large number of facilities may represent more generalizable results. Next, database entry can lead to patient coding and classification errors, and the study has potential for selection bias given patients are from CoC accredited hospitals. While the database has a wide variety of coding variables, the NCDB does not describe key clinical details such as the extent of END performed, number of procedures, and detailed procedural findings. This lack of treatment data limits the ability to identify all factors influencing treatment outcomes. Over the length of this retrospective series, grading of histologic subtypes has been changed, which would alter tumor diagnosis retrospectively and lead to an inherent limitation. Even with the limitations, the present study provides meaningful epidemiological information and treatment outcomes about patients with T1-2, N0 MEC of the parotid gland.

5 CONCLUSION

In this large analysis of patients with T1-2, N0 MEC of the parotid gland, we found that T classification was upstaged 11.52% of the time, and the facial nerve was preserved in 74.7% of patients. We found that END is routinely performed in T1-2, N0 MEC of the parotid gland, but there was no observed difference in OS. Additionally, utilization of adjuvant RT did not appear to improve OS. These findings provide meaningful information to help physicians counsel patients preoperatively with early stage MEC of the parotid gland.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

DATA AVAILABILITY STATEMENT
The data-using agreement prohibits sharing data. The data are available by application to the sponsoring agency, the American College of Surgeons.

ORCID
Zaid Al-Qurayshi © https://orcid.org/0000-0002-3534-7253
REFERENCES

1. Panwar A, Kozel JA, Lydiatt WM. Cancers of major salivary glands. *Surg Oncol Clin N Am*. 2015;24(3):615-633. doi:10.1016/j.soc.2015.03.011

2. Aro K, Leivo I, Mäkitie AA. Management and outcome of patients with mucoepidermoid carcinoma of major salivary gland origin: a single institution’s 30-year experience. *Laryngoscope*. 2008;118(2):258-262. doi:10.1097/MLG.0b013e3181a6b0b

3. Boahene DKO, Olsen KD, Lewis JE, Pinheiro AD, Pankratz VS, Bagnwieski SM. Mucoepidermoid carcinoma of the parotid gland. *Arch Otolaryngol Neck Surg*. 2004;130(7):849. doi:10.1001/archotol.130.7.849

4. Nance MA, Seethala RR, Wang Y, et al. Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. *Cancer*. 2008;113(8):2082-2089. doi:10.1002/cncr.23825

5. McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. *Arch Pathol Lab Med*. 2009;133(11):1763-1774. doi:10.1043/1543-2165-133.11.1763

6. Bishop JA, Cowan ML, Shum CH, Westra WH. MAML2 rearrangements in variant forms of Mucoepidermoid carcinoma: ancillary diagnostic testing for the ciliated and Warthin-like variants. *Am J Surg Pathol*. 2018;42(1):130-136. doi:10.1097/PAS.0000000000000932

7. Chiosea SI, Dacic S, Nikiforova MN, Seethala RR. Prospective testing of mucoepidermoid carcinoma for the MAML2 translocation: clinical implications. *Laryngoscope*. 2012;122(8):1690-1694. doi:10.1002/lary.22419

8. Seethala RR, Dacic S, Clepky K, Kelly LM, Nikiforova MN. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. *Am J Surg Pathol*. 2010;34(8):1106-1121. doi:10.1097/PAS.0b013e3181de3021

9. Cipriani NA, Lusardi JJ, McElherne J, et al. Mucoepidermoid carcinoma: a comparison of histologic grading systems and relationship to MAML2 rearrangement and prognosis. *Am J Surg Pathol*. 2019;43(7):885-897. doi:10.1097/PAS.0000000000001252

10. Pires FR, de Almeida OP, de Araújo VC, Kowalski LP. Prognostic factors in head and neck mucoepidermoid carcinoma. *Arch Otolarangol Head Neck Surg*. 2004;130(2):174-180. doi:10.1016/j.archotol.2003.12.174

11. Rajasekaran K, Stubbs V, Chen J, et al. Mucoepidermoid carcinoma of the parotid gland: A National Cancer Database study. *Am J Otolarangol*. 2018;39(3):321-326. doi:10.1016/j.amjotol.2018.03.022

12. Zenga J, Yu Z, Parikh A, et al. Mucoepidermoid carcinoma of the parotid: very close margins and adjuvant radiotherapy. *ORL J Otorhinolaryngol Relat Spec*. 2019;81(1):55-62. doi:10.1159/000497438

13. Rizk S, Robert A, Vandenhoof A, Airlordi M, Kornek G, Machiels J-P. Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. *Eur Arch Otorhinolaryngol*. 2007;264(6):587-594. doi:10.1007/s00405-007-0297-x

14. National Cancer Data Base. https://www.facs.org/quality-programs/cancer/ncdb. Accessed 19 February 2021.

15. Kılıç SS, Kılıç S, Crippen MM, et al. Predictors of clinical-pathologic stage discrepancy in oral cavity squamous cell carcinoma: a National Cancer Database study. *Head Neck*. 2018;40(4):828-836. doi:10.1002/hed.25065

16. Smith SL, Komisar A. Limited parotidectomy: the role of extracapsular dissection in parotid gland neoplasms. *Laryngoscope*. 2007;117(7):1163-1167. doi:10.1097/MLG.0b013e31806009fe

17. Mantopoulos K, Velegrakis S, Iro H. Unexpected detection of parotid gland malignancy during primary extracapsular dissection. *Otolarangol Head Neck Surg*. 2015;152(6):1042-1047. doi:10.1177/0194599815578104

18. Mantopoulos K, Koch M, Iro H. Extracapsular dissection as sole therapy for small low-grade malignant tumors of the parotid gland. *Laryngoscope*. 2017;127(8):1804-1807. doi:10.1002/lary.26482

19. Guntinas-Lichius O, Thieler J, Robbins KT, et al. Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: systematic review. *Head Neck*. 2021;43(3):997-1008. doi:10.1002/hed.26541

20. Moss WJ, Coffey CS, Brumund KT, Weisman RA. What is the role of elective neck dissection in low-, intermediate-, and high-grade mucoepidermoid carcinoma? *Laryngoscope*. 2016;126(1):11-13. doi:10.1002/lary.25588

21. Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. *Cancer*. 1992;69(3):615-619. doi:10.1002/1097-0142(19920201)69:3<2:2-9>

22. Lau VH, Aouad R, Farwell DG, Donald PJ, Chen AM. Patterns of nodal involvement for clinically N0 salivary gland carcinoma: refining the role of elective neck irradiation. *Head Neck*. 2014;36(10):1435-1439. doi:10.1002/hed.23467

23. National Comprehensive Cancer Network Guidelines. https://www.nccn.org/professionals/physician_gls/default.aspx?site. Published 2021. Accessed 6 April 2021.

24. Akbaba S, Heusel A, Mock A, et al. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: a 15-year single-center experience. *Oral Oncol*. 2019;97:115-123. doi:10.1016/j.joraloncology.2019.08.018

25. Okumura Y, Murase T, Saida K, et al. Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3-MAML2 fusions. *Head Neck*. 2018;40(12):2565-2573. doi:10.1002/hed.24856

26. Swendsen B, Li S, Thuener J, et al. Incidence of facial nerve sacrifice in parotidectomy for primary and metastatic malignancies. *Oral Oncol*. 2017;73:43-47. doi:10.1016/j.joraloncology.2017.07.029

27. Gandolfi MM, Slattery W. Parotid gland tumors and the facial nerve. *Oral Oncol*. 2017;73:43-47. doi:10.1016/j.oraloncology.2019.08.018

How to cite this article: Al-Qurayshi Z, Sullivan CB, Allison DB, Buchakjian MR. Presentation and outcomes of patients with clinically T1-2, N0 parotid mucoepidermoid carcinoma: The roles of elective neck dissection and adjuvant radiotherapy. *Head & Neck*. 2022;44(10):2151-2161. doi:10.1002/hed.27128